抗缪勒氏管激素在多囊卵巢综合征中的研究 进展
Research Progress of Anti-Müllerian Hormone in Polycystic Ovary Syndrome
DOI: 10.12677/acm.2026.1641265, PDF,   
作者: 勾露玉, 马莹莹, 王 玉：延安大学医学院，陕西 延安；张媛媛：延安大学附属医院妇产科生殖医学中心，陕西 延安
关键词: 抗缪勒氏管激素；多囊卵巢综合征；抗缪勒氏管激素受体II型；AMH； PCOS； AMHRII
摘要: 抗缪勒氏管激素(AMH)作为卵巢储备的重要标志物，被发现与多囊卵巢综合征(PCOS)的发病机制密切相关，近年来研究发现抗缪勒氏管激素(AMH)已成为诊断多囊卵巢综合征(PCOS)的一项重要指标。本文系统阐述了AMH在多囊卵巢综合征(PCOS)病理生理过程中的作用机制，包括其对卵泡发育、下丘脑–垂体–卵巢轴功能、胰岛素抵抗及高雄激素血症的调控作用，并进一步探讨了其作为PCOS诊断标志物与治疗靶点的潜在临床应用价值。
Abstract: Anti-Müllerian hormone (AMH), as an important biomarker of ovarian reserve, has been found to be closely related to the pathogenesis of polycystic ovary syndrome (PCOS). In recent years, it has been discovered that AMH has become an important indicator for the diagnosis of PCOS. This article systematically expounds the mechanism of AMH in the pathophysiological process of PCOS, including its regulatory effects on follicular development, hypothalamic-pituitary-ovarian axis function, insulin resistance and hyperandrogenemia, and further explores its potential clinical application value as a diagnostic marker and therapeutic target for PCOS.
文章引用：勾露玉, 马莹莹, 王玉, 张媛媛. 抗缪勒氏管激素在多囊卵巢综合征中的研究 进展[J]. 临床医学进展, 2026, 16(4): 429-435. https://doi.org/10.12677/acm.2026.1641265

参考文献

[1] Teede, H.J., Tay, C.T., Laven, J.J.E., Dokras, A., Moran, L.J., Piltonen, T.T., et al. (2023) Recommendations from the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology & Metabolism, 108, 2447-2469. [Google Scholar] [CrossRef] [PubMed]
[2] di Clemente, N., Racine, C., Pierre, A. and Taieb, J. (2021) Anti-Müllerian Hormone in Female Reproduction. Endocrine Reviews, 42, 753-782. [Google Scholar] [CrossRef] [PubMed]
[3] Josso, N. (1990) Anti-Müllerian Hormone: Hormone or Growth Factor? Progress in Growth Factor Research, 2, 169-179. [Google Scholar] [CrossRef] [PubMed]
[4] Josso, N., Lamarre, I., Picard, J., Berta, P., Davies, N., Morichon, N., et al. (1993) Anti-Müllerian Hormone in Early Human Development. Early Human Development, 33, 91-99. [Google Scholar] [CrossRef] [PubMed]
[5] Visser, J.A., de Jong, F.H., Laven, J.S.E. and Themmen, A.P.N. (2006) Anti-Müllerian Hormone: A New Marker for Ovarian Function. Reproduction, 131, 1-9. [Google Scholar] [CrossRef] [PubMed]
[6] Josso, N. and Clemente, N.D. (2003) Transduction Pathway of Anti-Müllerian Hormone, a Sex-Specific Member of the TGF-β Family. Trends in Endocrinology & Metabolism, 14, 91-97. [Google Scholar] [CrossRef] [PubMed]
[7] Durlinger, A.L.L., Gruijters, M.J.G., Kramer, P., Karels, B., Kumar, T.R., Matzuk, M.M., et al. (2001) Anti-Müllerian Hormone Attenuates the Effects of FSH on Follicle Development in the Mouse Ovary. Endocrinology, 142, 4891-4899. [Google Scholar] [CrossRef] [PubMed]
[8] Cimino, I., Casoni, F., Liu, X., Messina, A., Parkash, J., Jamin, S.P., et al. (2016) Novel Role for Anti-Müllerian Hormone in the Regulation of GnRH Neuron Excitability and Hormone Secretion. Nature Communications, 7, Article No. 10055. [Google Scholar] [CrossRef] [PubMed]
[9] Garrel, G., Racine, C., L’Hôte, D., Denoyelle, C., Guigon, C.J., di Clemente, N., et al. (2016) Anti-Müllerian Hormone: A New Actor of Sexual Dimorphism in Pituitary Gonadotrope Activity before Puberty. Scientific Reports, 6, Article No. 23790. [Google Scholar] [CrossRef] [PubMed]
[10] Garrel, G., Denoyelle, C., L’Hôte, D., Picard, J., Teixeira, J., Kaiser, U.B., et al. (2019) GnRH Transactivates Human AMH Receptor Gene via Egr1 and FOXO1 in Gonadotrope Cells. Neuroendocrinology, 108, 65-83. [Google Scholar] [CrossRef] [PubMed]
[11] Barbotin, A.L., Mimouni, N.E.H., Kuchcinski, G., Lopes, R., Viard, R., Rasika, S., et al. (2023) Hypothalamic Neuroglial Plasticity Is Regulated by Anti-Müllerian Hormone and Disrupted in Polycystic Ovary Syndrome. eBioMedicine, 90, Article 104535. [Google Scholar] [CrossRef] [PubMed]
[12] Silva, M.S.B. and Giacobini, P. (2021) New Insights into Anti-Müllerian Hormone Role in the Hypothalamic-Pituitary-Gonadal Axis and Neuroendocrine Development. Cellular and Molecular Life Sciences, 78, 1-16. [Google Scholar] [CrossRef] [PubMed]
[13] Pellatt, L., Rice, S., Dilaver, N., Heshri, A., Galea, R., Brincat, M., et al. (2011) Anti-Müllerian Hormone Reduces Follicle Sensitivity to Follicle-Stimulating Hormone in Human Granulosa Cells. Fertility and Sterility, 96, 1246-1251. [Google Scholar] [CrossRef] [PubMed]
[14] Halder, A., Kumar, H., Sharma, M., Jain, M., Kalsi, A.K. and Pandey, S. (2023) Serum Anti-Müllerian Hormone: A Potential Biomarker for Polycystic Ovary Syndrome. Indian Journal of Medical Research, 158, 397-406. [Google Scholar] [CrossRef] [PubMed]
[15] Ran, Y., Yi, Q. and Li, C. (2021) The Relationship of Anti-Mullerian Hormone in Polycystic Ovary Syndrome Patients with Different Subgroups. Diabetes, Metabolic Syndrome and Obesity, 14, 1419-1424. [Google Scholar] [CrossRef] [PubMed]
[16] Timur, H.T., Cimrin, D., Gursoy Doruk, O. and Dogan, O.E. (2023) Determining the Age Group-Based Cut-Off Values of Serum Anti-Mullerian Hormone Concentrations to Diagnose Polycystic Ovary Syndrome. Current Medical Research and Opinion, 39, 855-863. [Google Scholar] [CrossRef] [PubMed]
[17] Ata, C., Atlihan, U., Avsar, H.A., Yavuz, O., Erkilinc, S. and Bildaci, T.B. (2025) The Relationship of Antimullerian Hormone with Severity of Clinical Symptoms in Polycystic Ovary Syndrome. BMC Women’s Health, 25, Article No. 432. [Google Scholar] [CrossRef] 
[18] Piltonen, T.T., Kinnunen, J., Komsi, E., Kangasniemi, M.H., Luiro, K., Rajecki, M., et al. (2025) Prospective Validation of Anti-Müllerian Hormone Cutoff to Determine Polycystic Ovarian Morphology: HARMONIA Study. Fertility and Sterility, 124, 543-552. [Google Scholar] [CrossRef] [PubMed]
[19] Gao, X., Zhao, S., Du, Y., Yang, Z., Tian, Y., Zhao, J., et al. (2025) Author Correction: Data-Driven Subtypes of Polycystic Ovary Syndrome and Their Association with Clinical Outcomes. Nature Medicine, 31, 4314-4314. [Google Scholar] [CrossRef] 
[20] Wang, Z., Teng, X., Liu, Y., Shen, Y., Ma, L. and Chen, Y. (2025) Establishment of Age-Related AMH Screening Cutoffs in Chinese Women with PCOS: A Retrospective Study Using Propensity Score Matching Analysis. BMC Endocrine Disorders, 25, Article No. 153. [Google Scholar] [CrossRef] [PubMed]
[21] Ke, Y., Tang, D., Yang, Q., Zhao, H., Zheng, J. and Zhu, C. (2025) Anti-Müllerian Hormone in PCOS: Molecular Regulation and Emerging Therapeutic Strategies. Biomolecules and Biomedicine, 26, 173-185. [Google Scholar] [CrossRef] [PubMed]
[22] 多囊卵巢综合征诊治路径专家共识编写组. 多囊卵巢综合征诊治路径专家共识[J] 中华生殖与避孕杂志, 2023, 43(4): 337-345.
[23] Li, X.J., Wang, H., Lu, D., Yu, T., Ullah, K., Shi, X., et al. (2021) Anti-Müllerian Hormone Accelerates Pathological Process of Insulin Resistance in Polycystic Ovary Syndrome Patients. Hormone and Metabolic Research, 53, 504-511. [Google Scholar] [CrossRef] [PubMed]
[24] Vagios, S., Hsu, J.Y., Sacha, C.R., Dimitriadis, I., Christou, G., James, K.E., et al. (2021) Pretreatment Anti-Müllerian Hormone Levels and Outcomes of Ovarian Stimulation with Gonadotropins/Intrauterine Insemination Cycles. Fertility and Sterility, 116, 422-430. [Google Scholar] [CrossRef] [PubMed]
[25] Hsu, J.Y., James, K.E., Bormann, C.L., Donahoe, P.K., Pépin, D. and Sabatini, M.E. (2018) Müllerian-Inhibiting Substance/Anti-Müllerian Hormone as a Predictor of Preterm Birth in Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology & Metabolism, 103, 4187-4196. [Google Scholar] [CrossRef] [PubMed]
[26] 中华医学会妇产科学分会内分泌学组及指南专家组. 多囊卵巢综合征中国诊疗指南[J]. 中华妇产科杂志, 2018, 53(1): 2-6.
[27] 马思晨, 闫洪超. 多囊卵巢综合征合并代谢综合征患者血清AMH水平、窦卵泡计数变化及其意义[J]. 山东医药, 2023, 63(4): 82-84.
[28] Md Muslim, M.Z., Mohammed Jelani, A., Shafii, N., Yaacob, N.M., Che Soh, N.A.A. and Ibrahim, H.A. (2024) Correlation between Anti-Mullerian Hormone with Insulin Resistance in Polycystic Ovarian Syndrome: A Systematic Review and Meta-Analysis. Journal of Ovarian Research, 17, Article No. 106. [Google Scholar] [CrossRef] [PubMed]
[29] Yao, Y., Zhu, S. and Zhu, X. (2024) PCOS Influences the Expression of AMHRII in the Endometrium of AEH during the Reproductive Age. Diagnostics, 14, Article 2872. [Google Scholar] [CrossRef] [PubMed]
[30] Kim, S.I., Yoon, J.H. and Hur, S.Y. (2021) Functional Profiles of Müllerian Inhibiting Substance/Anti-Müllerian Hormone (MIS/AMH) in Primarily Cultured Endometrial Cancer Cells. Journal of Cancer, 12, 6289-6300. [Google Scholar] [CrossRef] [PubMed]
[31] Kim, S.Y., Moon, H.M., Lee, M.K., Chung, Y.J., Song, J.Y., Cho, H.H., et al. (2018) The Expression of Müllerian Inhibiting Substance/Anti-Müllerian Hormone Type II Receptor in Myoma and Adenomyosis. Obstetrics & Gynecology Science, 61, 127-134. [Google Scholar] [CrossRef] [PubMed]
[32] Howard, J.A., Hart, K.N. and Thompson, T.B. (2022) Molecular Mechanisms of AMH Signaling. Frontiers in Endocrinology, 13, Article 927824. [Google Scholar] [CrossRef] [PubMed]
[33] Prat, M., Salon, M., Allain, T., Dubreuil, O., Noël, G., Preisser, L., et al. (2021) Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation. Cancers, 13, Article No. 1845. [Google Scholar] [CrossRef] [PubMed]
[34] Li, Y., Wei, L., Meinsohn, M., Suliman, R., Chauvin, M., Berstler, J., et al. (2022) A Screen of Repurposed Drugs Identifies AMHR2/MISR2 Agonists as Potential Contraceptives. Proceedings of the National Academy of Sciences, 119, e2122512119. [Google Scholar] [CrossRef] [PubMed]
[35] Chauvin, M., Garambois, V., Colombo, P., Chentouf, M., Gros, L., Brouillet, J., et al. (2021) Anti-Müllerian Hormone (AMH) Autocrine Signaling Promotes Survival and Proliferation of Ovarian Cancer Cells. Scientific Reports, 11, Article No. 2231. [Google Scholar] [CrossRef] [PubMed]
[36] Zhao, H., Xu, Y., Xue, B., Zhao, S., Zhang, M., Wu, X., et al. (2025) Multi-Ancestry Genome-Wide Association Analyses of Polycystic Ovary Syndrome. Nature Genetics, 57, 2669-2681. [Google Scholar] [CrossRef] 

为你推荐